Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer

Clinical Trial ID NCT00140556

PubWeight™ 4.75^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00140556

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules.	Cancer Cell	2004	6.99
2	Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.	N Engl J Med	1998	5.20
3	Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer.	Int J Radiat Oncol Biol Phys	2001	2.59
4	Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome.	Radiother Oncol	1999	2.25
5	The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications.	Radiat Oncol	2006	1.13
6	Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer.	Clin Cancer Res	2012	1.11
7	Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications.	Front Immunol	2015	0.92
8	Relation between pO2, 31P magnetic resonance spectroscopy parameters and treatment outcome in patients with high-grade soft tissue sarcomas treated with thermoradiotherapy.	Int J Radiat Oncol Biol Phys	2005	0.87
9	Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer.	Int J Radiat Oncol Biol Phys	2007	0.86
10	Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters.	Int J Radiat Oncol Biol Phys	2011	0.80